
Gini F Fleming

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10063343/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. Lancet Oncology, The, 2014, 15, 1207-1214.	10.7	523
2	Current recommendations and recent progress in endometrial cancer. Ca-A Cancer Journal for Clinicians, 2019, 69, 258-279.	329.8	366
3	Chemotherapy-induced peripheral neuropathy: Current status and progress. Gynecologic Oncology, 2016, 140, 176-183.	1.4	196
4	The role of postoperative radiation therapy for endometrial cancer: Executive Summary of an American Society for Radiation Oncology evidence-based guideline. Practical Radiation Oncology, 2014, 4, 137-144.	2.1	151
5	Induction of Neoantigen-Specific Cytotoxic T Cells and Construction of T-cell Receptor–Engineered T Cells for Ovarian Cancer. Clinical Cancer Research, 2018, 24, 5357-5367.	7.0	70
6	Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer – An NRG oncology/Gynecologic Oncology Group study. Gynecologic Oncology, 2017, 144, 459-467.	1.4	61
7	Glucocorticoid receptor activation inhibits chemotherapy-induced cell death in high-grade serous ovarian carcinoma. Gynecologic Oncology, 2015, 138, 656-662.	1.4	57
8	Characterization of T cell repertoire of blood, tumor, and ascites in ovarian cancer patients using next generation sequencing. Oncolmmunology, 2015, 4, e1030561.	4.6	52
9	Discovery of a Glucocorticoid Receptor (GR) Activity Signature Using Selective GR Antagonism in ER-Negative Breast Cancer. Clinical Cancer Research, 2018, 24, 3433-3446.	7.0	49
10	Association of Metformin Use with Outcomes in Advanced Endometrial Cancer Treated with Chemotherapy. PLoS ONE, 2016, 11, e0147145.	2.5	41
11	The Application and Outcome of Standard of Care Treatment in Elderly Women with Ovarian Cancer: A Literature Review over the Last 10 Years. Frontiers in Oncology, 2016, 6, 63.	2.8	37
12	A phase I trial of escalating doses of trastuzumab combined with daily subcutaneous interleukin 2: report of cancer and leukemia group B 9661. Clinical Cancer Research, 2002, 8, 3718-27.	7.0	36
13	Glucocorticoid receptor modulation decreases ER-positive breast cancer cell proliferation and suppresses wild-type and mutant ER chromatin association. Breast Cancer Research, 2019, 21, 82.	5.0	35
14	A randomized phase I trial of nanoparticle albumin-bound paclitaxel with or without mifepristone for advanced breast cancer. SpringerPlus, 2016, 5, 947.	1.2	29
15	High glucocorticoid receptor expression predicts short progression-free survival in ovarian cancer. Gynecologic Oncology, 2017, 146, 153-160.	1.4	28
16	Epigenetic priming enhances antitumor immunity in platinum-resistant ovarian cancer. Journal of Clinical Investigation, 2022, 132, .	8.2	28
17	Impact of post-diagnosis weight change on survival outcomes in Black and White breast cancer patients. Breast Cancer Research, 2021, 23, 18.	5.0	27
18	Racial disparities in survival outcomes among breast cancer patients by molecular subtypes. Breast Cancer Research and Treatment, 2021, 185, 841-849.	2.5	25

GINI F FLEMING

#	Article	IF	CITATIONS
19	Phase I clinical and pharmacokinetic study of oral 9-aminocamptothecin (NSC-603071). Cancer Chemotherapy and Pharmacology, 1998, 42, 84-87.	2.3	23
20	Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors. Clinical Cancer Research, 2021, 27, 5510-5518.	7.0	23
21	Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: NCI clinical trials planning meeting report on identifying key genes and molecular pathways for targeted endometrial cancer trials. Oncotarget, 2017, 8, 84579-84594.	1.8	23
22	Therapeutic Targets and Opportunities in Endometrial Cancer: Update on Endocrine Therapy and Nonimmunotherapy Targeted Options. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, 245-255.	3.8	19
23	A phase I study of oral uracil/ftorafur (UFT) plus leucovorin and bis-acetato-ammine-dichloro-cyclohexylamine-platinum IV (JM-216) each given over 14 days every 28 days. Cancer Chemotherapy and Pharmacology, 1999, 43, 385-388.	2.3	17
24	Glucocorticoid receptor expression is associated with inferior overall survival independent of BRCA mutation status in ovarian cancer. International Journal of Gynecological Cancer, 2019, 29, 357-364.	2.5	15
25	Expression of glucocorticoid receptor is associated with aggressive primary endometrial cancer and increases from primary to metastatic lesions. Gynecologic Oncology, 2017, 147, 672-677.	1.4	14
26	No Exit: Identifying Avoidable Terminal Oncology Intensive Care Unit Hospitalizations. Journal of Oncology Practice, 2016, 12, e901-e911.	2.5	13
27	A pharmacodynamic study of sirolimus and metformin in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2018, 82, 309-317.	2.3	12
28	Double-blind, randomized crossover study of metoclopramide and batanopride for prevention of cisplatin-induced emesis. Cancer Chemotherapy and Pharmacology, 1991, 28, 226-227.	2.3	10
29	Sustained Complete Response to Cytotoxic Therapy and the PARP Inhibitor Veliparib in Metastatic Castration-Resistant Prostate Cancer – A Case Report. Frontiers in Oncology, 2015, 5, 169.	2.8	10
30	Overcoming Taxane Resistance: Preclinical and Phase 1 Studies of Relacorilant, a Selective Glucocorticoid Receptor Modulator, with Nab-Paclitaxel in Solid Tumors. Clinical Cancer Research, 2022, 28, 3214-3224.	7.0	10
31	Leptomeningeal carcinomatosis from breast cancer treated with intrathecal topotecan with concomitant intravenous eribulin. Journal of Clinical Neuroscience, 2014, 21, 1250-1251.	1.5	8
32	Immune checkpoint inhibitors in women with gynecologic cancers: Practical considerations. Gynecologic Oncology, 2020, 158, 531-537.	1.4	8
33	Healthâ€related quality of life outcomes for the LEAP study—CALGB 70305 (Alliance): A lymphedema prevention intervention trial for newly diagnosed breast cancer patients. Cancer, 2021, 127, 300-309.	4.1	8
34	Phase I study of escalating doses of mitoxantrone and paclitaxel with granulocyte-macrophage colony stimulating factor support. , 1996, 77, 2308-2312.		4
35	Successful treatment of squamous cell carcinoma arising from a presumed ovarian mature cystic teratoma with pembrolizumab. Gynecologic Oncology Reports, 2021, 37, 100837.	0.6	4
36	Serum C-Telopeptide Collagen Crosslinks and Plasma Soluble VEGFR2 as Pharmacodynamic Biomarkers in a Trial of Sequentially Administered Sunitinib and Cilengitide. Clinical Cancer Research, 2015, 21, 5092-5099.	7.0	3

GINI F FLEMING

#	Article	IF	CITATIONS
37	Small cell carcinoma of the ovary, pulmonary type: A role for adjuvant radiotherapy after carboplatin and etoposide?. Gynecologic Oncology Reports, 2022, 39, 100925.	0.6	3
38	Tumor board presentation of a woman with metastatic, hormone receptorâ€positive, mismatch repairâ€deficient endometrial cancer. Ca-A Cancer Journal for Clinicians, 2022, 72, 102-111.	329.8	3
39	Development of a schedule-dependent population pharmacodynamic model for rhizoxin without quantitation of plasma concentrations. Cancer Chemotherapy and Pharmacology, 2000, 45, 489-494.	2.3	2
40	Topotecan in the treatment of ovarian cancer. Expert Review of Obstetrics and Gynecology, 2006, 1, 149-158.	0.4	1
41	Effects of Slide Storage on Detection of Molecular Markers by IHC and FISH in Endometrial Cancer Tissues From a Clinical Trial. Applied Immunohistochemistry and Molecular Morphology, 2021, Publish Ahead of Print, 27-35.	1.2	1
42	Adjuvant Endocrine Therapy for Hormone Receptor-Positive Early Breast Cancer in Premenopausal Patient: Understanding the Data. Current Breast Cancer Reports, 2015, 7, 183-189.	1.0	0